title: Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer.
authors.affiliation: Department of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland christian.rothermundt@kssg.ch.
authors.forename: C
authors.initials: C
authors.lastname: Rothermundt
authors.affiliation: Department of Radiology and Nuclear Medicine, Kantonsspital St Gallen, St Gallen, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Hader
authors.affiliation: Department of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Gillessen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077784:Axitinib; D000068258:Bevacizumab / Q000627:therapeutic use; D001929:Brain Edema / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007191:Indazoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011832:Radiation Injuries / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068258:Bevacizumab; C516667:pazopanib; D000077784:Axitinib; C582435:pembrolizumab